Cervical neuroendocrine carcinoma (CNEC)
Conditions
Interventions
Patients with cervical neuroendocrine carcinoma:None
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed cervical neuroendocrine carcinoma via surgical or biopsy specimens, including subtypes such as small cell and large cell neuroendocrine carcinoma. 2. Primary tumor originating from the cervix, with no prior history of primary malignancies in other organs. 3. Female patients aged 18 to 75 years old. 4. Complete clinical and imaging data with clear FIGO staging and assessment of lymph node and distant metastasis status. 5. Treatment-naive patients who have not received radiotherapy, chemotherapy, targeted therapy, immunotherapy or neoadjuvant therapy (to ensure the original tumor heterogeneity is not altered by anti-tumor treatments). 6. Residual tumor tissue specimens are available for collection (archived samples from biobanks, pathology departments or leftover clinical diagnostic specimens).
Exclusion criteria
Exclusion criteria: 1. Patients with a history of other malignant tumors, double primary cancers or multiple primary neoplasms. 2. Patients who received anti-tumor therapies including neoadjuvant chemotherapy, radiotherapy, targeted therapy, or immunotherapy prior to enrollment. 3. Tissue specimens with severe necrosis or hemolysis that fail to generate qualified single-cell suspensions. 4. Patients complicated with severe infection, autoimmune diseases, severe liver or renal failure, or other conditions interfering with experiments and follow-up. 5. Patients with incomplete clinicopathological and imaging data that cannot support stratified analysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactYin Zhuomin
Zhejiang Cancer Hospital
Outcome results
None listed